Search Results 101-110 of 21952 for Parkinson's disease
The Neurobiology of Parkinson's Disease Lab seeks to determine if excess toxic intermediate species of alpha-synuclein can lead to proteasome dysfunction.
But here's one thing you might not have heard: Ongoing aerobic exercise may slow the progression of Parkinson's disease, a progressive disorder of the nervous ...
View faculty and staff of Mayo Clinic's Parkinson's Disease Lab led by Owen A. Ross, Ph.D.
Read news highlighting gene studies in Parkinson's disease from Mayo Clinic's Translational Cell Biology of Parkinson's Disease Lab led by Wolfdieter ...
Cytoplasmic deposition of alpha-synuclein aggregates is a common pathological feature of many neurodegenerative synucleinopathies, including Parkinson's ...
ROCHESTER, Minn. — Sept. 18, 2013 — A genetic mutation, known as GBA, that leads to early onset of Parkinson's disease and severe cognitive impairment (in ...
This high-risk group was followed by patients with Lewy body dementia, four years earlier; Parkinson disease dementia, 3½ years earlier; and Parkinson disease, ...
... Parkinson's disease. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...
... Parkinson's disease and its potential as a target for neuroprotective therapies. It has also been the focus of multiple efforts to develop a molecule that ...
Health care professionals can't diagnose Parkinson's disease until you have symptoms, which include shaking and slowed movement. But in the research setting, an ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Last chance! Your gift today has 5X the power to fuel medical progress using AI.